The opinions expressed by columnists are their own and do not represent our advertisers

Friday, December 22, 2017

Stop-smoking drug increases users' risk of a heart attack

A stop-smoking drug increases users' risk of a heart attack by up to 34 percent, new research suggests.

Varenicline, which is prescribed under the brand name Chantix in the US and Champix in Europe, significantly raises users' chances of being hospitalized or visiting an emergency room for a cardiovascular-related event even if it is taken for the recommended 12 weeks, a Canadian study found.

The drug is also linked to self-harm and depression in older users, the research adds.

Previous research suggests this is due to varenicline's action on receptors found in tissues throughout the body.

Varenicline increases a smoker's chances of quitting by nearly three times by reducing nicotine cravings and blocking the rewarding effects of smoking.

A 12-week course of varenicline is one of the most effective ways to help people quit smoking, according to the NHS' website.

It says the drug is safe for most people to take and does not mention its cardiovascular or neuropsychiatric side effects aside from insomnia and vivid dreams.



Anonymous said...

After 52 years of smoking, over 3 1/2 packs/day for a foot portion, ten years later no interest even when around those who still do. This looks like someone trying to avoid a great solution.

Anonymous said...

Explain "foot portion", please. Kudos on your quitting!!๐Ÿ‘๐Ÿ‘๐Ÿ‘

Anonymous said...

Good portion

Anonymous said...

You are still going to die.